Ignite Creation Date:
2024-05-05 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 9:52 AM
Study NCT ID:
NCT00714948
Status:
TERMINATED
Last Update Posted:
2015-11-16
First Post:
2008-07-10
Brief Title:
Gemcitabine and Split-dose Cisplatin GC Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase II Study of Gemcitabine and Split-dose Cisplatin GC Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
TERMINATED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients Gemcitabine and Cisplatin are an effective and standard drug combination used to treat locally advanced and metastatic urothelial cancer However these drugs do not shrink tumors in all patients and when they do it is generally for a limited amount of time This has led scientists to look for different ways to treat cancer
New drugs have been developed to treat cancer that work differently than standard chemotherapy drugs These drugs attempt to decrease the blood supply to tumors By doing so this may limit the tumors source of oxygen and nutrients and prevent the tumor from growing Sorafenib is an example of a drug that works in this way
In some patients with advanced kidney cancer sorafenib alone has been shown to slow the progression of their disease The purpose of this study is to find out what effects good andor bad the combination of gemcitabine cisplatin and sorafenib has on you and your cancer
New drugs have been developed to treat cancer that work differently than standard chemotherapy drugs These drugs attempt to decrease the blood supply to tumors By doing so this may limit the tumors source of oxygen and nutrients and prevent the tumor from growing Sorafenib is an example of a drug that works in this way
In some patients with advanced kidney cancer sorafenib alone has been shown to slow the progression of their disease The purpose of this study is to find out what effects good andor bad the combination of gemcitabine cisplatin and sorafenib has on you and your cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None